Relay Therapeutics (RLAY) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Relay Therapeutics (RLAY) over the last 5 years, with Q3 2025 value amounting to -$0.43.
- Relay Therapeutics' EPS (Weighted Average and Diluted) rose 3174.6% to -$0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.72, marking a year-over-year increase of 3409.96%. This contributed to the annual value of -$2.36 for FY2024, which is 1541.22% up from last year.
- Latest data reveals that Relay Therapeutics reported EPS (Weighted Average and Diluted) of -$0.43 as of Q3 2025, which was up 3174.6% from -$0.41 recorded in Q2 2025.
- In the past 5 years, Relay Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.41 during Q2 2025, and its lowest value of -$0.81 during Q2 2023.
- For the 5-year period, Relay Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.61, with its median value being -$0.62 (2024).
- In the last 5 years, Relay Therapeutics' EPS (Weighted Average and Diluted) crashed by 3684.21% in 2023 and then surged by 4057.97% in 2025.
- Quarter analysis of 5 years shows Relay Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.62 in 2021, then grew by 11.29% to -$0.55 in 2022, then decreased by 21.82% to -$0.67 in 2023, then soared by 37.31% to -$0.42 in 2024, then dropped by 2.38% to -$0.43 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.43 in Q3 2025, compared to -$0.41 in Q2 2025 and -$0.46 in Q1 2025.